Newer intranasal migraine medications.
Am Fam Physician
; 61(1): 180-6, 2000 Jan 01.
Article
em En
| MEDLINE
| ID: mdl-10643958
ABSTRACT
Two new intranasal migraine medications, sumatriptan and dihydroergotamine mesylate, may offer specific advantages for patients who are seeking alternatives to various oral or parenteral migraine abortive therapies. Placebo-controlled clinical studies demonstrate that both intranasal forms are effective in relieving migraine headache pain, but published clinical trial information comparing these two intranasal medications with current abortive therapies is lacking. Both agents are generally well tolerated by patients, with the exception of mild, local adverse reactions of the nose and throat.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Agonistas do Receptor de Serotonina
/
Sumatriptana
/
Analgésicos não Narcóticos
/
Oxazolidinonas
/
Di-Hidroergotamina
/
Transtornos de Enxaqueca
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
Am Fam Physician
Ano de publicação:
2000
Tipo de documento:
Article
País de afiliação:
Estados Unidos